RXi Awarded NIGMS Grant to Improve Self-Delivering RNAi Agents | GenomeWeb

RXi Pharmaceuticals last month won a six-month grant from the National Institute of General Medical Sciences worth $273,824 to make improvements to its self-delivering RNAi technology.

With the funding, RXi plans to develop a panel of second-generation self-delivering RNAi molecules, called sd-rxRNAs, with “improved potency and pharmacology by incorporating modified nucleotide bases with lipophilic moieties,” according to the grant's abstract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."